Convincing evidence exists from preclinical studies that the ratio of Tdp1/Top1 activity influences cellular sensitivity to Top1 inhibitors [34,35], and that the suppression of Tdp1 activity leads to an increase in the sensitivity of tumor cells to CPTs [32,36,37,38,39]. Here, TDP1 is linked to neoplasm.